Advanced Renal Cell Carcinoma: Balancing Efficacy and Quality of Life Through Dose Optimization

In this segment, the discussion focuses on optimizing treatment in advanced renal cell carcinoma by balancing efficacy with long-term tolerability and quality of life. Dr. Elizabeth Plimack explains that while initial therapy is often started at higher doses to achieve rapid and effective disease control, subsequent dose adjustments are frequently necessary to manage treatment-related adverse effects. She introduces the concept of finding a “cruising altitude,” where disease remains controlled while minimizing toxicity. Dr. Brian Rini reinforces this approach, emphasizing that the goal is not to maximize dose intensity but to maintain effective disease control with the lowest tolerable dose. Both experts highlight the importance of proactive patient counseling to address concerns around dose reductions, as patients may associate higher doses with better outcomes. The segment underscores that individualized dose optimization and ongoing communication are essential to sustaining long-term treatment benefit in advanced renal cell carcinoma.